Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently conducting a Phase 3 clinical study, officially titled ‘Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study).’ The study aims to evaluate the safety, tolerability, event-free survival (EFS), and overall survival (OS) of blinatumomab alternating with low-intensity chemotherapy compared to standard of care chemotherapy in older adults with this specific type of leukemia.
The intervention being tested includes the drug Blinatumomab, administered via continuous intravenous infusion, alternating with a low-intensity chemotherapy regimen. This approach is compared to the standard of care chemotherapy regimens, which are administered in various forms including intravenous, oral, subcutaneous, or intrathecal.
The study is interventional, with participants randomly assigned to either the experimental or standard treatment groups. It follows a parallel intervention model without masking, focusing primarily on treatment outcomes.
Key dates for the study include its start date on July 30, 2021, and the latest update submitted on October 24, 2025. These timelines are crucial as they indicate the study’s progression and the anticipated timeline for results.
For investors, this study update could signal potential growth for Amgen’s stock, especially if the results favor the experimental treatment. The study’s progress may also influence investor sentiment positively, given the competitive landscape in the leukemia treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.